Growth Hormone Release Inhibiting Hormone in Acromegaly

Besser, G. M.; Mortimer, C. H.; Carr, D.; Schally, A. V.; Coy, D. H.; Evered, D.; Kastin, A. J.; Tunbridge, W. M. G.; Thorner, M. O.; Hall, R.
March 1974
British Medical Journal;3/2/1974, Vol. 1 Issue 5904, p352
Academic Journal
No abstract available.


Related Articles

  • Long term treatment of acromegaly with a long acting analogue of somatostatin. Ch'ng, L.J.C.; Sandler, L.M.; Kraenzlin, M.E.; Burrin, J.M.; Joplin, G.F.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);1/26/1985, Vol. 290 Issue 6464, p284 

    Examines the long term treatment of acromegaly using somatostatin. Inhibition of secretion of growth hormone in patients with acromegaly; Relation between active acromegaly and increase morbidity and mortality; Concentrations of growth hormone before and following the treatment with selective...

  • acromegaly.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p34 

    An encyclopedia entry for "acromegaly," which is a syndrome of excessive secretion of growth hormone, is presented.

  • Section II hormonal causes. Sotos, Juan F. // Clinical Pediatrics;Nov1996, Vol. 35 Issue 11, p579 

    Focuses on excessive secretion of growth hormones. Pituitary gigantism and acromegaly; Manifestations in gigantism and acromegaly.

  • Acromegaly: treatment after 100 years. Wass, J.A.H. // BMJ: British Medical Journal (International Edition);12/11/93, Vol. 307 Issue 6918, p1505 

    Comments on the treatment of acromegaly. Increase in the morbidity and mortality among patients with acromegaly; Aims of the treatment; Concentration of growth hormones.

  • Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor (GRF (1-44)) in acromegaly and hypopituitarism. Wood, S.M.; Ch'ng, J.C.L.; Adams, E.F.; Webster, J.D.; Joplin, G.F.; Mashiter, K.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);5/28/1983, Vol. 286 Issue 6379, p1687 

    Examines the effects of human pancreatic growth hormone releasing factor [GRF [1-44]] to growth hormone release in patients with hypopituitarism and acromegaly. Clinical and biochemical features of patients with acromegaly; Characteristics of patients with impaired pituitary function; Use of...

  • Circulating growth hormone releasing factor concentrations in normal subjects and patients with acromegaly. Penny, Elizabeth S.; Penman, Erica; Price, Janet; Rees, Lesley H.; Sopwith, A.M.; Wass, J.A.H.; Lytras, N.; Besser, G.M. // British Medical Journal (Clinical Research Edition);8/25/1984, Vol. 289 Issue 6443, p453 

    Examines the circulating growth hormone releasing factor (GRF) concentrations in patients with and without acromegaly in Great Britain. Measurement by radioimmunoassay; Evaluation of GRF concentrations in plasma samples;.

  • Modern treatment of acromegaly. Merza, Z. // Postgraduate Medical Journal;Apr2003, Vol. 79 Issue 930, p189 

    Acromegaly is an endocrine disorder characterised by increased morbidity and mortality. It is usually caused by a growth hormone secreting pituitary adenoma and is manifested by a variety of clinical features. Surgery is usually the treatment of choice, however over the last few years, several...

  • Too stressed to grow.  // Joe Weider's Muscle & Fitness;Feb95, Vol. 56 Issue 2, p26 

    Reports on the possibility that the stress hormone cortisol inhibits growth hormone release. Effect of depression; Insight on testing procedure.

  • Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly. Sandler, L.M.; Burrin, J.M.; Joplin, G.F.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);3/12/1988, Vol. 296 Issue 6624, p751 

    Investigates the biochemical effects of increasing doses of octreotide in patients with acromegaly. Administration of octreotide in patient with active acromegaly; Decrease in growth hormone and insulin concentrations; Normalization of growth hormone concentration by subcutaneous octreotide.

  • Long-term treatment of acromegaly with bromocriptine. Wass, J.A.H.; Thorner, M.O.; Morris, D.V.; Rees, Lesley H.; Mason, A. Stuart; Jones, A.E.; Besser, G.M. // British Medical Journal;4/2/1977, Vol. 1 Issue 6065, p875 

    Examines the effectiveness of bromocriptine on the log-term treatment of acromegaly. Decline of the mean circulating growth hormones; Suppression of the growth hormone during the long-term management of acromegaly; Side effects of bromocriptine.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics